MASS News & Events

908 Devices announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Otitoju brings over 25 years of proven executive leadership in strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of Strategy & Business Development at Repligen Corporation.

908 Devices files $100M mixed securities shelf

The company said, "908 Devices expects full year 2026 revenues to be in the range of $64.5 million to $67.5 million, representing 15% to 20% growth compared to 2025 revenue from continuing operations."

Reports Q4 revenue $17.38M, consensus $16.19M. "2025 was a defining year for 908 Devices as we strengthened our operating model, expanded margins, and achieved Adjusted EBITDA positivity in the fourth quarter. Our disciplined execution led to strong growth as we achieved revenue of $56.2 million in 2025, an 18% increase year over year," said Kevin J. Knopp, CEO and Co-founder. "The structural changes we have implemented combined with a solid balance sheet give us financial flexibility to focus resources on the growing demand across the vital health, safety, and defense-tech markets we serve."